Citation Report
List of articles citing

Plasma tau levels in Alzheimer s disease

DOI: 10.1186/alzrt163
Alzheimer s Research and Therapy, 2013, 5, 9.

Source: https://exaly.com/paper-pdf/54765430/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
301	Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. **2013**, 16, 424-8		24
300	Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. **2014**, 9, 969-80		284
299	Proteins as biomarkers of carbon monoxide neurotoxicity. **2014**, 26, 885-90		9
298	Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. **2014**, 39, 189-201		54
297	Antibody-based proteomics and biomarker research - current status and limitations. **2014**, 14, 774-83		83
296	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. **2014**, 261, 1234-43		29
295	Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. **2014**, 5, 830-6		81
294	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. **2014**, 88, 426-49		84
293	Progress update: fluid and imaging biomarkers in Alzheimer's disease. **2014**, 75, 520-6		18
292	Anti-tau antibody reduces insoluble tau and decreases brain atrophy. **2015**, 2, 278-88		119
291	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. **2016**, 50, 539-46		28
290	Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology. **2016**, 50, 111-26		15
289	Biomarkers in Sporadic and Familial Alzheimer's Disease. **2015**, 47, 291-317		61
288	A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. **2015**, 3, 2050312115598250		15
287	The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease. **2015**, 6, 90		15
286	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. **2015**, 6, 186		19
285	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. **2015**, 6, 236		77

284	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. **2015**, 6, 256		10
283	Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria. **2015**, 449, 3-8		22
282	Fluid markers of traumatic brain injury. **2015**, 66, 99-102		35
281	Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. **2015**, 132, 135-45		57
280	Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. **2015**, 21, 217-9		52
279	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. **2015**, 11, 1461-1469		95
278	Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease. **2015**, 74, 32-40		4
277	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. **2015**, 11, 600-7.e1		479
276	Femtomolar Detection of Tau Proteins in Undiluted Plasma Using Surface Plasmon Resonance. **2016**, 88, 7793-9		48
275	Update on fluid biomarkers for concussion. **2016**, 1, CNC12		4
274	Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients. *Alzheimer's Research and Therapy*, **2016**, 8, 43	9	9
273	Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. **2016**, 51, 1099-109		105
272	Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease. **2017**, 55, 1595-1603		14
271	The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. **2016**, 7, 520-7		53
270	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. **2016**, 12, 1125-1131		99
269	Single frequency analysis for clinical immunosensor design. **2016**, 6, 281-289		5
268	Blood-based biomarkers in Alzheimer's disease: an overview on proteomic and lipidomic approaches. **2016**, 24, 143-152		
267	Plasma tau in Alzheimer disease. **2016**, 87, 1827-1835		269

266	Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty. **2016**, 14, 3184-98	13
265	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. **2016**, 3, 98-102	47
264	Fluid biomarkers for mild traumatic brain injury and related conditions. **2016**, 12, 563-74	150
263	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. **2016**, 12, 1226-1234	82
262	Traumatic brain injuries. **2016**, 2, 16084	245
261	Using Antigen-antibody Binding Kinetic Parameters to Understand Single-Molecule Array Immunoassay Performance. **2016**, 88, 11335-11339	14
260	The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain. **2016**, 31, 99-105	6
259	Fluid Biomarkers and Diagnostics. **2016**, 565-587	
258	The roles of inflammation and immune mechanisms in´Alzheimer's´disease. **2016**, 2, 99-109	124
257	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. **2016**, 17, 251-60	198
256	Alzheimer's disease. **2016**, 388, 505-17	1720
255	Review: Tau in biofluids - relation to pathology, imaging and clinical features. **2017**, 43, 194-199	88
254	Repetitive head impact exposure and later-life plasma total tau in former National Football League players. **2017**, 7, 33-40	58
253	An amylin analog used as a challenge test for Alzheimer's disease. **2017**, 3, 33-43	10
252	Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. **2017**, 131, 1-15	29
251	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. **2017**, 88, 961-969	58
250	Applying fluid biomarkers to Alzheimer's disease. **2017**, 313, C3-C10	35
249	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. **2017**, 9,	58

248	Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. **2017**, 58, 471-478	12
247	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. **2017**, 58, 1245-1254	41
246	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. **2017**, 88, 883-888	16
245	Single-Molecule Arrays for Protein and Nucleic Acid Analysis. **2017**, 10, 345-363	64
244	Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model. **2017**, 56, 47-61	28
243	Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. **2017**, 89, 2167-2175	154
242	Tandem Femto- and Nanomolar Analysis of Two Protein Biomarkers in Plasma on a Single Mixed Antibody Monolayer Surface Using Surface Plasmon Resonance. **2017**, 89, 12562-12568	13
241	Long-Term Measurements of Human Inflammatory Cytokines Reveal Complex Baseline Variations between Individuals. **2017**, 187, 2620-2626	22
240	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. **2017**, 7, 9529	20
239	Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. **2017**, 114, E7929-E7938	79
238	Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. **2017**, 7, 9304	29
237	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. **2017**, 6, 15-24	141
236	Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies. **2017**, 6, 25-36	72
235	On comparing 2 correlated C indices with censored survival data. **2017**, 36, 4041-4049	12
234	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. **2017**, 24, 1326-e77	55
233	A Preliminary Study on Investigation of Serum Synuclein and Tau Protein Levels in Children with Attention Deficit Hyperactivity Disorder. **2017**, 32, 285-291	5
232	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. **2017**, 74, 1073-1080	108
231	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. **2017**, 14, 35-53	78

230	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. **2017**, 21, 13-22	26
229	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. **2017**, 13, 45-58	163
228	The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. **2017**, 13, 8-19	162
227	The Distinction of Amyloid-Protein Precursor (APP) Ratio in Platelet Between Alzheimer's Disease Patients and Controls: A Systematic Review and Meta-Analysis. **2017**, 59, 1037-1044	4
226	Animal Models of Acquired Epilepsy and Tauopathies. **2017**, 1031-1041	2
225	Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults. **2017**, 9, 51	12
224	Plasma Levels of A42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts. **2017**, 9, 226	64
223	Study on Analysis of Peripheral Biomarkers for Alzheimer's Disease Diagnosis. **2017**, 8, 328	26
222	Biomarkers for Alzheimer Disease. **2017**, 247-277	
221	Increased levels of plasma total tau in adult Down syndrome. **2017**, 12, e0188802	30
220	Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. **2017**, 12, 63	140
219	Neuroinflammation in Alzheimer's disease: Pleiotropic roles for cytokines and neuronal pentraxins. **2018**, 347, 49-56	33
218	Blood-based immunoassay of tau proteins for early diagnosis of Alzheimer's disease using surface plasmon resonance fiber sensors.. **2018**, 8, 7855-7862	23
217	Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. **2018**, 89, 955-961	46
216	Recent developments with tau-based drug discovery. **2018**, 13, 399-410	26
215	Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. **2018**, 35, 2351-2356	27
214	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. **2018**, 14, 989-997	217
213	An investigation of neuroinjury biomarkers after sport-related concussion: from the subacute phase to clinical recovery. **2018**, 32, 575-582	12

212	The Past and the Future of Alzheimer's Disease Fluid Biomarkers. **2018**, 62, 1125-1140	69
211	Plasma A analysis using magnetically-labeled immunoassays and PET F-florbetapir binding in non-demented patients with major depressive disorder. **2018**, 8, 2739	3
210	Progress and Challenges in the Diagnosis of Dementia: A Critical Review. **2018**, 9, 446-461	16
209	Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease. **2018**, 61, 1323-1332	70
208	Surface Enhanced Raman Spectroscopy for Medical Diagnostics. **2018**, 1-66	6
207	A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers. **2018**, 101, 96-102	68
206	Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. **2018**, 114, 3-9	45
205	Introduction. 1-16	2
204	Chronic traumatic encephalopathy: fluid biomarkers. **2018**, 158, 323-333	9
203	Lost and Found. 133-154	2
202	Presuming the Promotion of the Common Good by Large-Scale Health Research. 155-182	0
201	Current state of Alzheimer's fluid biomarkers. **2018**, 136, 821-853	236
200	Stem Cell-Derived Gametes and Uterus Transplants. 37-51	
199	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. **2018**, 14, 639-652	257
198	Plasma Markers of Neurodegeneration Are Raised in Friedreich's Ataxia. **2018**, 12, 366	21
197	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. **2018**, 84, 648-658	137
196	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. **2018**, 17, 860-869	105
195	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. **2018**, 64, S271-S279	44

194	Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: A prospective study. **2018**, 13, e0194802	11
193	No association of salivary total tau concentration with Alzheimer's disease. **2018**, 70, 125-127	35
192	Biomarkers for Alzheimer's disease: current status and prospects for the future. **2018**, 284, 643-663	278
191	Eight-Channel AC Magnetosusceptometer of Magnetic Nanoparticles for High-Throughput and Ultra-High-Sensitivity Immunoassay. **2018**, 18,	8
190	Molecular biomarkers of Alzheimer's disease: progress and prospects. **2018**, 11,	109
189	Raman Spectroscopy to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies in Blood. **2018**, 9, 2786-2794	38
188	Metallomics Applied to the Study of Neurodegenerative and Mental Diseases. **2018**, 1055, 21-37	9
187	A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging. **2019**, 71, 57-82	11
186	Molecular Marker and Therapeutic Regimen for Neurodegenerative Diseases. **2019**, 13-41	
185	AD biomarker discovery in CSF and in alternative matrices. **2019**, 72, 52-57	11
184	Size-Controllable Magnetic Iron Oxide Nanorods for Biomarker Targeting and Improving Microfluidic Mixing.. **2019**, 2, 3362-3371	4
183	Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. **2019**, 11, 483-492	48
182	Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. **2019**, 6, 157-163	39
181	Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias. **2019**,	4
180	Primary fatty amides are potential plasma biomarkers for AD. **2019**, 15, 498-499	
179	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. **2019**, 20,	25
178	Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study. **2019**, 8,	13
177	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. **2019**, 7, 5	79

176	Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease. **2019**, 2019, 7406810	10
175	Plasma A42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment. **2019**, 9, 13984	26
174	Plasma tau/amyloid-1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. **2019**, 142, 771-786	76
173	Improving Sensitivity and Specificity of Amyloid-Peptides and Tau Protein Detection with Antibiofouling Magnetic Nanoparticles for Liquid Biopsy of Alzheimer's Disease. **2019**, 5, 3595-3605	16
172	Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. **2019**, 6, 169-173	23
171	Potential Value of Plasma Amyloid-Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. **2019**, 10, 3479-3485	26
170	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. **2019**, 76, 969-977	39
169	Plasma Biomarkers: Potent Screeners of Alzheimer's Disease. **2019**, 34, 290-301	7
168	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. **2019**, 203, 84-92	14
167	Synchronous screening of multiplexed biomarkers of Alzheimer's disease by a length-encoded aerolysin nanopore-integrated triple-helix molecular switch. **2019**, 55, 6433-6436	16
166	Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. **2019**, 76, 598-606	87
165	Increased Ratio of Global -GlcNAcylation to Tau Phosphorylation at Thr212 Site Is Associated With Better Memory Function in Patients With Type 2 Diabetes. **2019**, 10, 110	1
164	Blood-based molecular biomarkers for Alzheimer's disease. **2019**, 12, 26	100
163	Therapeutic Role of Transcranial Direct Current Stimulation in Alzheimer Disease Patients: Double-Blind, Placebo-Controlled Clinical Trial. **2019**, 33, 384-394	19
162	Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration. **2019**, 13, 326	0
161	A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent. **2019**, 4, 595-602	27
160	Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. **2019**, 8, 95-111	10
159	Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. **2019**, 167, 139-148	28

158	Identifying Alzheimer's disease-related proteins by LRRGD. **2019**, 20, 570	9
157	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. **2019**, 168, 3-23	11
156	In Longitudinal Framingham Study, Total Tau Levels in Blood Rise Years Before a Diagnosis of Dementia. **2019**, 19, 5-6	
155	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. **2019**, 12, 1756286419888819	14
154	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. **2019**, 8, 129-145	6
153	Salivary Biomarkers for Alzheimer's Disease and Related Disorders. **2019**, 8, 83-94	24
152	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. **2019**, 151, 397-416	18
151	Head trauma in sports - clinical characteristics, epidemiology and biomarkers. **2019**, 285, 624-634	22
150	Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. **2019**, 15, 487-496	60
149	Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease. **2019**, 16, 3	21
148	Blood-based biomarkers for Alzheimer's disease-An update. **2019**, 319, 2-6	55
147	Biomarkers for tau pathology. **2019**, 97, 18-33	96
146	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. **2019**, 151, 417-434	10
145	Tau Is Elevated in Pediatric Patients on Extracorporeal Membrane Oxygenation. **2020**, 66, 91-96	1
144	From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. **2020**, 139, 3-25	65
143	Exploring Relationships Among Peripheral Amyloid Beta, Tau, Cytokines, Cognitive Function, and Psychosomatic Symptoms in Breast Cancer Survivors. **2020**, 22, 126-138	9
142	Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma. **2020**, 11, 119	51
141	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. **2020**, 94, e30-e41	13

140	Surface plasmon resonance biosensors for detection of Alzheimer's biomarkers; an effective step in early and accurate diagnosis. **2020**, 167, 112511	27
139	Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice. **2020**, 13, 106	0
138	Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression. **2020**, 21,	20
137	Adenosine and Metabotropic Glutamate Receptors Are Present in Blood Serum and Exosomes from SAMP8 Mice: Modulation by Aging and Resveratrol. **2020**, 9,	1
136	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. **2020**, 10,	10
135	An in vitro bioengineered model of the human arterial neurovascular unit to study neurodegenerative diseases. **2020**, 15, 70	3
134	Systems Biology Methods Applied to Blood and Tissue for a Comprehensive Analysis of Immune Response to Hepatitis B Vaccine in Adults. **2020**, 11, 580373	8
133	Fluid Biomarkers for Chronic Traumatic Encephalopathy. **2020**, 40, 411-419	2
132	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. **2020**, 10,	4
131	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. **2020**, 324, 772-781	268
130	Blood-Based Biomarkers for Predictive Diagnosis of Cognitive Impairment in a Pakistani Population. **2020**, 12, 223	4
129	Multiplexed femtomolar detection of Alzheimer's disease biomarkers in biofluids using a reduced graphene oxide field-effect transistor. **2020**, 167, 112505	25
128	Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. **2020**, 217,	102
127	A Robust Blood-based Signature of Cerebrospinal Fluid A Status. **2020**, 2020, 5523-5526	1
126	The pathway to secondary prevention of Alzheimer's disease. **2020**, 6, e12069	1
125	Current Biomarkers for Alzheimer's Disease: From CSF to Blood. **2020**, 10,	13
124	Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. **2020**, 88, 878-892	8
123	Saliva Biomarkers in Diagnostics of Early Stages of Alzheimer Disease. **2020**, 14, 429-438	2

122	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. **2020**, 11, 6252		15
121	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer's Disease. **2020**, 10,		1
120	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. **2020**, 94, 60-70		13
119	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. **2020**, 21,		4
118	Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology. **2020**, 15, e0234519		3
117	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. *Alzheimer's Research and Therapy*, **2020**, 12, 74	9	18
116	Blood Biomarkers of Cognitive Health and Neurodegenerative Disease. **2020**, 568-586		
115	Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study. **2020**, 28, 102182		9
114	Profile of Pathogenic Proteins and MicroRNAs in Plasma-derived Extracellular Vesicles in Alzheimer's Disease: A Pilot Study. **2020**, 432, 240-246		14
113	Identifying Protein Biomarkers in Blood for Alzheimer's Disease. **2020**, 8, 472		6
112	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. **2020**, 49, 5446-5472		25
111	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. **2020**, 26, 379-386		292
110	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. *Alzheimer's Research and Therapy*, **2020**, 12, 20	9	13
109	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. **2020**, 89, 99-107		18
108	Serum tau as a predictor for neurological outcome after cardiopulmonary resuscitation. **2020**, 148, 207-214		3
107	Femtomolar sensing of Alzheimer's tau proteins by water oxidation-coupled photoelectrochemical platform. **2020**, 154, 112075		12
106	Long Noncoding RNA POU3F3 and Synuclein in Plasma L1CAM Exosomes Combined with Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease. **2020**, 17, 1104-1119		15
105	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. **2020**, 16, 265-284		53

104	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. **2021**, 185, 108081	12
103	Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. **2021**, 144, 288-309	33
102	Plasma Biomarkers of Alzheimer's Disease in African Americans. **2021**, 79, 323-334	3
101	Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. **2021**, 79, 177-195	9
100	Differential effects of putative N-glycosylation sites in human Tau on Alzheimer's disease-related neurodegeneration. **2021**, 78, 2231-2245	7
99	Serum-neuroproteins, near-infrared spectroscopy, and cognitive outcome after beach-chair shoulder surgery: Observational cohort study analyses. **2021**, 65, 26-33	0
98	High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples. **2021**, 4, 34-44	1
97	Requirement of brain interleukin33 for aquaporin4 expression in astrocytes and glymphatic drainage of abnormal tau. **2021**,	6
96	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. **2021**, 34, 266-274	14
95	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. **2021**, 13, e12168	12
94	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. **2021**, 18, 27-48	3
93	Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. **2020**, 11, 573324	9
92	Plasma P-tau181 to A42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. **2021**, 17, 1649-1662	12
91	Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis. **2021**, 10, 10	6
90	Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease. **2021**, 19, 72	10
89	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. **2021**, 48, 2140-2156	31
88	Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease. **2021**, 15, 7357-7369	5
87	An Introduction to Ultrasensitive Assays for Plasma Tau Detection. **2021**, 80, 1353-1362	1

86	State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm. **2021**, 11,	4
85	Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease. **2021**, 80, 1067-1077	4
84	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. **2021**, 92, 1206-1214	10
83	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. **2021**, 290, 583-601	15
82	Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer's Disease: A Systematic Review and Meta-Analysis. **2021**, 11,	5
81	A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers. **2021**,	2
80	ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease. **2021**, 80, 652-662	1
79	Curiosity-Based Interventions Increase Everyday Functioning Score But Not Serum BDNF Levels in a Cohort of Healthy Older Adults. **2021**, 2,	
78	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. **2021**, 159, 211-233	8
77	The Amyloid-Pathway in Alzheimer's Disease. **2021**,	63
76	Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease. **2021**, 9,	0
75	Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends. **2022**, 97-128	
74	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. **2021**, 17, 1145-1156	48
73	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. **2020**, 12, e12099	8
72	ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins. **2018**, 247, 138-155	92
71	Modifiable risk factors promoting neurodegeneration is associated with two novel brain degradation markers measured in serum. **2017**, 108, 303-308	2
70	The Molecularised Me. 245-260	2
69	Platelet miRNA bio-signature discriminates between dementia with Lewy bodies and Alzheimer disease.	0

68	Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood. **2020**, 19, 1-18	4
67	Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients. **2016**, 11, e0159099	43
66	Altered Blood Biomarker Profiles in Athletes with a History of Repetitive Head Impacts. **2016**, 11, e0159929	29
65	Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. **2016**, 11, e0164953	16
64	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. **2020**, 42, 431-441	18
63	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. **2019**, 21, 177-191	13
62	Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis. **2020**, 10,	6
61	The Microbiota-Gut-Brain Axis and Alzheimer's Disease: Neuroinflammation Is to Blame?. **2020**, 13,	31
60	Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam-era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD-ADNI) study. **2021**, 13, e12239	2
59	Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. **2021**, 144, 255-261	0
58	Proteomic Approaches for Diagnostics of Canine and Feline Dementia. **2017**, 113-127	
57	Personalised Medicine, Individual Choice and the Common Good. **2018**,	2
56	Alzheimer's disease brain-derived tau-containing extracellular vesicles: Pathobiology and GABAergic neuronal transmission.	
55	Combating the Trade in Organs. 77-112	1
54	Alzheimer's disease biomarkers in animal models: closing the translational gap. **2013**, 2, 108-20	13
53	Detection of Alzheimer's Disease. **2018**, 91, 291-300	17
52	Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future. **2021**, 209, 114479	0
51	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. **2021**, 11, 22675	4

50	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. **2021**,	40
49	Highly sensitive surface-enhanced Raman scattering-based immunosensor incorporating half antibody-fragment for quantitative detection of Alzheimer's disease biomarker in blood.. **2022**, 1195, 339445	4
48	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.. **2022**,	2
47	Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis.. **2021**, 13, 807764	2
46	Paving the way for reliable Alzheimer's disease blood diagnosis by quadruple electrochemical immunosensing.	0
45	Grip Strength, Gait Speed and Plasma Markers of Neurodegeneration in Asymptomatic Middle-aged and Older Adults. 1	0
44	Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies.. **2022**, 129, 239	1
43	Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels.. **2022**,	
42	Associations between cerebrospinal fluid markers and cognition in aging and dementia: A systematic review.. **2022**,	0
41	The Early Prognostic Value and Optimal Time of Measuring Serum and Cerebrospinal Fluid Tau Protein for Neurologic Outcomes in Postcardiac Arrest Patients Treated with Targeted Temperature Management.. **2022**,	
40	Development of Fluid Biomarkers for Alzheimer Disease. **2022**, 361-374	
39	Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels.. **2022**, 5, 336	0
38	Recent advances in blood and gut microbiota biomarkers for Alzheimer’s disease. **2021**,	
37	Plasma biomarkers for diagnosis of Alzheimer disease and prediction of cognitive decline in individuals with mild cognitive impairment.	0
36	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.. **2022**,	
35	Image_1.TIF. **2020**,	
34	Table_1.xlsx. **2020**,	
33	Advances in the development of new biomarkers for Alzheimer's disease.. **2022**, 11, 25	2

32	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.. **2022**,	4
31	Long-Term Effects of Repeated Blast Exposure in United States Special Operations Forces Personnel: A Pilot Study Protocol
.	
30	Tau as a Biomarker of Neurodegeneration. **2022**, 23, 7307	4
29	Very high hyperbilirubinaemia in neonates to identify brain injury, neuron-specific enolase, calcium binding protein B, glial fibrillary acidic protein, Tau protein and growth differentiation factor 5 levels.	
28	Proteomic Markers and Early Prediction of Alzheimer Disease. **2022**, 87, 762-776	
27	Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer Disease. **2022**, 10, 1879	
26	Fluid biomarkers and risk of neurodegenerative disease in retired athletes with multiple concussions: results from the International Concussion and Head Injury Research Foundation Brain health in Retired athletes Study of Ageing and Impact-Related Neurodegenerative Disease (ICHIRF-BRAIN study). **2022**, 8, e001327	0
25	Cognitive Resilience in Brain Health and Dementia Research. **2022**, 1-13	1
24	Plasma phosphorylated tau 181 predicts amyloid status and conversion from mild cognitive impairment to dementia stage; major impact of renal function on diagnostic performance in the BALTAZAR cohort.	0
23	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer disease. 14,	0
22	Alzheimer's disease diagnosis by blood plasma molecular fluorescence spectroscopy (EEM). **2022**, 12,	1
21	Quantitative proteomics of tau and A in detergent fractions from Alzheimer's disease brains.	1
20	Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients. 2,	0
19	Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges. **2022**,	1
18	Brain-derived tau: a novel blood-based biomarker for Alzheimer disease-type neurodegeneration.	1
17	Single-molecule fluorescence methods for protein biomarker analysis.	0
16	Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma. 14,	0
15	Omic-Based Biomarkers Discovery in Alzheimer Disease: High-Throughput Approaches. **2023**, 1-18	0

14	Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. jnnp-2022-330540	0
13	Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. **2022**, 16, 25-39	0
12	. 306-308	0
11	My Genome, My Right. 183-199	0
10	Personalised Medicine and the Politics of Human Nuclear Genome Transfer. 17-36	0
9	Index. 302-305	0
8	Bibliography. 261-301	0
7	I Run, You Run, We Run. 226-244	0
6	Personalising Future Health Risk through Biological Insurance 52-76	0
5	The Best Me I Can Possibly Be 200-225	0
4	When There Is No Cure. 113-132	0
3	Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. **2022**, 16, 25-39	0
2	Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment. 14,	0
1	Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden.	0